Bibliography:
1. Keogh RH, Szczesniak R, Taylor-Robinson D, Bilton D. Up-to-date and
projected estimate for people with cystic fibrosis using baseline
characteristics: a longitudinal study using UK patient registry data. J
Cyst Fibros 2018; 17: 218-227.
2. Stephenson AL, Tom M,
Berthiaume Y, Singer LG, Aaron SD, Whitmore GA, Stanojevic S. A
contemporary survival analysis of individuals with cystic fibrosis: a
cohort study. Eur Resp J 2015; 45: 670-679.
3. MacKenzie T, Gifford AH, Sabadosa KA, Quinton HB, Knapp EA, Goss CH,
Marshall BC. Longevity of patients with cystic fibrosis in 2000-2010 and
beyond: survival analysis of the Cystic Fibrosis Foundation Patient
Registry. Ann Intern Med 2014: 161: 233-241.
4. Farrell PM, Lai HJ, Li Z, Kosorok MR, Laxova A, Green CG, Collins J,
Hoffman G, Laessig R, Rock MJ, Splaingard ML. Evidence on improved
outcomes with early diagnosis of cystic fibrosis through neonatal
screening: enough is enough! J Pediatr 2005; 147:
S30-36.
5. Tridello G, Castellini C, Menegheilli I,
Tamanini A, Assael BM. Early diagnosis from newborn screening maximizes
survival in severe cystic fibrosis. ERJ Open Res 2017: 20; 4:00109-2017.
doi: 10.1183/23120541.00109-2017.
6. Sanders DB, Zhang Z, Farrell PM, Lai HJ. Early life growth patterns
persist for 12 years and impact pulmonary outcomes in cystic fibrosis. J
Cyst Fibros 2018; 17: 528-535.
7. Morgan WJ, Wagener JS, Pasta DJ, Millar SJ, VanDeventer DR, Konstan
MW. Relationship of antibiotic treatment to recovery after acute FEV1
decline in children with cystic fibrosis. Ann Am Thorac Soc 2017; 6:
937-942.
8. Middleton PG, Mall MA, Drevinek P, et al.
Elexacaftor-tezacaftor-ivacaftor for cystic fibrosis with a single
Phe508del Allele. N Engl J Med 2019; 381: 1809-19.
9. Hayes D, Cherikh WS. Chamber DC, Harhay MO, Khush KK, Lehman RR,
Meiser B, Rossano JW, Hsich E, Potena L, Sadavarte A, Singh TP,
Zuckermann A, Stehlik J. The international Thoracic Organ Transplant
Registry of the International Society for Heart and Lung
Transplantation: twenty-second pediatric lung and heart-lung
transplantation report – 2019: focus theme: donor and recipient size
match. J Heart Lung Transplant 2019: 38: 105-1027.
10. Ramos KJ, Smith PJ, McKone EF, et al. Lung transplant referral for
individuals with cystic fibrosis: Cystic Fibrosis Foundation consensus
guidelines. J Cyst Fibros 2019; 18: 321-333.
11. Luna RA, Millecker LA, Webb R, Mason SK, Whaley EM, Starke JR, Hiatt
PW, Versalovic J. Molecular epidemiological suveiilance of multi-drug
resistant Pseudomonas aeruginosa isolates in a pediatric population of
patients with cystic fibrosis and determination of risk factors for
infection with the Houston-1 strain. J Clin Microbiol 2013: 51:
1237-1240.
12. Tracy MC, Moss RB. The myriad challenges of respiratory fungal
infection in cystic fibrosis. Pediatr Pulmonol 2018; 53: S75-S85.
13. Stern RC, Boat TF, Orenstein DM, Wood RE, Matthews LW, Doerschuk CF.
Treatment and prognosis of lobar and segmental atelecatasis in cystic
fibrosis. Am Rev Respir Dis 1978; 118: 821-826.
14. Marmon L, Schidlow D, Palmer J, Balsara RK, Dunn JM. Pulmonary
resection for complications of cystic fibrosis. J Pediatr Surg 1983; 18:
811-815.
15. Flight WG, Hildage J, Webb AK. Progressive unilateral lung collapse
in cystic fibrosis – a therapeutic challenge. J R Soc Med 2012; 105:
S44-S49.
16. Perrem L, Stanojevic S, Solomon M, Carpenter S, Ratjen F. Incidence
and risk factors of paediatric cystic fibrosis-related diabetes. J Cyst
Fibros 2019; 18: 874-878.
17. Moran A, Dunitz J, Nathan B, Saeed A, Home B, Thomas W. Cystic
fibrosis-related diabetes: current trends in prevalence, incidence, and
mortality. Diabetes care 2009; 32: 1626-1631.
18. Sanders DB, Slaven JE, Maguiness K, Chmiel JF, Ren CL. Early-life
height attainment in cystic fibrosis is associated with pulmonary
function at age 6 years. Ann Am Thorac Soc 2021: 18: DOI:
10.1513/AnnalsATS.202008-933OC.
19. Vanderheist E, De Meirleir L, Verbanck S, Pierard D, Vincken W,
Malfroot A. Prevalence and impact of FEV1 decline of chronic
methicillin-resistant Staphylococcus aureus (MRSA) colonization in
patients with cystic fibrosis: a single-center case control study of 165
patients. J Cyst Fibros 2021; 11: 2-7.
20. McColley SA, Schechter MS, Morgan WJ, Pasta DJ, Craib ML, Konstan
MW. Risk factors for mortality before age 18 years in cystic fibrosis.
Pediatr Pulmonol 2017; 52: 909-15.
21. Aurora P, Wade A, Whitmore P, Whitehead B. A model for predicting
life expectancy of children with cystic fibrosis. Eur Resp J 2000; 16:
1056-1060.
22. VanDeventer DR, Kahle JS, O’Sullivan AK, Sikirica S. Hodgkins PS.
Cystic fibrosis in young children: a review of disease manifestation,
progression, and response to early treatment. J Cyst Fibros 2016; 15:
147-157.
23. Moran A, Brunzell C, Cohen RC, Katz M, Marshall BC, Robinson KA,
Sabadosa KA, Stecenko A, Slovis B. Clinical care guidelines for cystic
fibrosis-related diabetes. Diabetes Care 2010; 33: 2697-2708.
24. Schechter MS, Margolis PA. Relationship between socioeconomic status
and disease severity in cystic fibrosis. J Pediatr 1998; 132: 260-264.
25. Schechter MS. Nongenetic influences on cystic fibrosis outcomes.
Curr Opin Pulm Med 2011; 17: 448-454.
26. Ong T, Schechter M, Yang J, Peng L, et al. Socioeconomic status,
smoke exposure and health outcomes in young children with cystic
fibrosis. Pediatrics. 2017; 139:e20162730
27. Mehta P, Steinberg EA, Kelly SL, Buchanan C, Rawlinson AR.
Medication adherence among adolescent solid-organ transplant recipients:
a survey of healthcare providers. Pediatr Transplant 2017; 21: doi:
10.1111/petr.13018.
28. Killian MO, Schuman DL, Mayersohn GS, Triplett KN. Psychosocial
predictors of medication non-adherence in pediatric organ
transplantation: a systematic review. Pediatr Transplant 2018; 22:
e13188.